Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack

• Verfasst von: Hankey, Graeme [VerfasserIn]
• Verfasst von: Hacke, Werner [VerfasserIn]
• Titel: Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack
• Titelzusatz: a subgroup analysis of ROCKET AF
• Verf.angabe: Graeme J Hankey, Manesh R Patel, Susanna R Stevens, Richard C Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A Donnan, Jonathan L Halperin, Kenneth W Mahaffey, Jean-Louis Mas, Ayrton Massaro, Bo Norrving, Christopher C Nessel, John F Paolini, Risto O Roine, Daniel E Singer, Lawrence Wong, Robert M Califf, Keith AA Fox, Werner Hacke, for the ROCKET AF Steering Committee and Investigators
• Umfang: 8 S.
• Fussnoten: Gesehen am 24.07.2018
• Titel Quelle: Enthalten in: The lancet <London> / Neurology
• Jahr Quelle: 2012
• Band/Heft Quelle: 11(2012), 4, S. 315-322
• ISSN Quelle: 1474-4465
• DOI: doi:10.1016/S1474-4422(12)70042-X
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1577904303

Abstract

Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).